Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish biopharmaceutical company Diamyd Medical has announced that a European patent has been granted for the use of nerve growth factors for the treatment of erectile dysfunction, also known as impotence. The company has an exclusive license for the patent, and patent applications have been filed in North America and Asia.
Subscribe to our email newsletter
Diamyd Medical’s US subsidiary, Diamyd Inc develops products based on the NTDDS-platform (nerve targeting drug delivery system). NTDDS is a system that can deliver therapeutics directly to the nerves.
This technology has been shown to be highly effective in direct delivery of nerve growth factors Neurturin, GDNF or NT3, and may be used in the future for prevention and treatment of erectile dysfunction caused by nerve damage, the company said.
Darren Wolfe, president of Diamyd Inc said: “Nerve damage related to prostate surgery is an acute situation where a single prophylactic dose of nerve growth factors delivered via NTDDS would be the entire treatment. This NTDDS-treatment could be amenable to outlicense or partnership.”